About Affomix
Affomix is a company based in New Haven (United States) founded in 2006 was acquired by Illumina in July 2010. Affomix has raised $7 million across 4 funding rounds from investors including Illumina, Four Seasons and HHS. Affomix operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter New Haven, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Affomix
Affomix has successfully raised a total of $7M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $111.35 thousand completed in May 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Affomix
Affomix has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Illumina, Four Seasons and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Locked | Locked | Locked | |
|
VC firm investing in seed & early stage companies in the US
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Affomix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Affomix
Investment portfolio details for Affomix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Affomix
Detailed financials for Affomix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Affomix Comparisons
Peer comparison for Affomix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Affomix
Affomix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
Detailed competitors of Affomix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Affomix
Complete news archive for Affomix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Affomix
Affomix was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Affomix is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Affomix is a funded company, having raised a total of $7M across 4 funding rounds to date.
Affomix was founded in 2006 in New Haven, United States, within the biotechnology sector. Proprietary technology is employed for rapid, automated selection of human monoclonal antibodies. Commercialization efforts focus on monoclonal antibodies, microarrays, and libraries applied in research, drug discovery, diagnostics, and therapeutics. Emphasis is placed on measuring large numbers of proteins in biological samples with sensitivity and accuracy. Operations are centered in the United States.
Affomix's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Affomix has 5 investors. Key investors include Illumina, Four Seasons, HHS, Elm Street Ventures, and Connecticut Innovations.